Is VSTM or NRIX more profitable?

Verastem has a net margin of -231.59% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Nurix Therapeutics -928.44% -76.09% -57.31%

Does the media prefer VSTM or NRIX?

In the previous week, Verastem had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 7 mentions for Verastem and 2 mentions for Nurix Therapeutics. Verastem's average media sentiment score of 0.27 beat Nurix Therapeutics' score of 0.00 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VSTM or CDNA?

CareDx has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 21.80 -$209.47M -$2.66 N/A CareDx $458.09M 6.08 -$21.35M $2.07 26.00

Is VSTM or CDNA more profitable?

CareDx has a net margin of 24.23% compared to Verastem's net margin of -231.59%. CareDx's return on equity of 2.87% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% CareDx 24.23% 2.87% 2.17%

Does the media favor VSTM or CDNA?

In the previous week, Verastem had 4 more articles in the media than CareDx. MarketBeat recorded 7 mentions for Verastem and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Verastem's score of 0.27 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VSTM or VERA?

In the previous week, Vera Therapeutics had 17 more articles in the media than Verastem. MarketBeat recorded 24 mentions for Vera Therapeutics and 7 mentions for Verastem. Vera Therapeutics' average media sentiment score of 0.65 beat Verastem's score of 0.27 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 8 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is VSTM or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Pharvaris' return on equity of -61.40% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Pharvaris N/A -61.40% -56.00%

Does the media prefer VSTM or PHVS?

In the previous week, Pharvaris had 18 more articles in the media than Verastem. MarketBeat recorded 25 mentions for Pharvaris and 7 mentions for Verastem. Pharvaris' average media sentiment score of 0.53 beat Verastem's score of 0.27 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 13 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, BEAM or VSTM?

Beam Therapeutics has higher revenue and earnings than Verastem. Beam Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beam Therapeutics $139.74M 18.44 -$79.99M -$0.86 N/A Verastem $30.91M 21.80 -$209.47M -$2.66 N/A

Is BEAM or VSTM more profitable?

Beam Therapeutics has a net margin of -54.75% compared to Verastem's net margin of -231.59%. Beam Therapeutics' return on equity of -30.71% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Beam Therapeutics -54.75% -30.71% -24.07% Verastem -231.59% -467.49% -94.54%

Does the media prefer BEAM or VSTM?

In the previous week, Verastem had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Verastem and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.50 beat Verastem's score of 0.27 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Verastem (VSTM) Competitors

$7.44 -0.11 (-1.46%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.52 +0.08 (+1.02%)

As of 09/18/2026 07:55 PM Eastern

Compare

VSTM vs. NRIX, CDNA, VERA, PHVS, and BEAM

Should you buy Verastem stock or one of its competitors? Verastem's main competitors and comparable companies include Nurix Therapeutics (NRIX), CareDx (CDNA), Vera Therapeutics (VERA), Pharvaris (PHVS), and Beam Therapeutics (BEAM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Verastem compare to Nurix Therapeutics?

Verastem (NASDAQ:VSTM) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Verastem has a net margin of -231.59% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Verastem had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 7 mentions for Verastem and 2 mentions for Nurix Therapeutics. Verastem's average media sentiment score of 0.27 beat Nurix Therapeutics' score of 0.00 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Verastem has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	21.80	-$209.47M	-$2.66	N/A
Nurix Therapeutics	$83.98M	31.44	-$264.46M	-$3.45	N/A

Verastem presently has a consensus price target of $13.83, suggesting a potential upside of 85.93%. Nurix Therapeutics has a consensus price target of $34.21, suggesting a potential upside of 34.49%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

88.4% of Verastem shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Verastem beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Verastem compare to CareDx?

Verastem (NASDAQ:VSTM) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Verastem has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, CareDx has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Verastem currently has a consensus target price of $13.83, suggesting a potential upside of 85.93%. CareDx has a consensus target price of $51.20, suggesting a potential downside of 4.89%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Verastem is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

CareDx has a net margin of 24.23% compared to Verastem's net margin of -231.59%. CareDx's return on equity of 2.87% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
CareDx	24.23%	2.87%	2.17%

88.4% of Verastem shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Verastem had 4 more articles in the media than CareDx. MarketBeat recorded 7 mentions for Verastem and 3 mentions for CareDx. CareDx's average media sentiment score of 0.88 beat Verastem's score of 0.27 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	21.80	-$209.47M	-$2.66	N/A
CareDx	$458.09M	6.08	-$21.35M	$2.07	26.00

Summary

CareDx beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Vera Therapeutics?

Verastem (NASDAQ:VSTM) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Vera Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Vera Therapeutics' return on equity of -84.13% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Vera Therapeutics	N/A	-84.13%	-66.79%

Verastem currently has a consensus price target of $13.83, suggesting a potential upside of 85.93%. Vera Therapeutics has a consensus price target of $80.15, suggesting a potential upside of 135.75%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

88.4% of Verastem shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vera Therapeutics had 17 more articles in the media than Verastem. MarketBeat recorded 24 mentions for Vera Therapeutics and 7 mentions for Verastem. Vera Therapeutics' average media sentiment score of 0.65 beat Verastem's score of 0.27 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	8 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	21.80	-$209.47M	-$2.66	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Verastem has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Vera Therapeutics beats Verastem on 11 of the 15 factors compared between the two stocks.

How does Verastem compare to Pharvaris?

Verastem (NASDAQ:VSTM) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Pharvaris has lower revenue, but higher earnings than Verastem. Pharvaris is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	21.80	-$209.47M	-$2.66	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

88.4% of Verastem shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharvaris has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Pharvaris' return on equity of -61.40% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Pharvaris	N/A	-61.40%	-56.00%

Verastem currently has a consensus price target of $13.83, suggesting a potential upside of 85.93%. Pharvaris has a consensus price target of $59.87, suggesting a potential upside of 64.60%. Given Verastem's stronger consensus rating and higher probable upside, research analysts plainly believe Verastem is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Pharvaris had 18 more articles in the media than Verastem. MarketBeat recorded 25 mentions for Pharvaris and 7 mentions for Verastem. Pharvaris' average media sentiment score of 0.53 beat Verastem's score of 0.27 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	13 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, indicating that its share price is 333% less volatile than the broader market.

Summary

Verastem and Pharvaris tied by winning 8 of the 16 factors compared between the two stocks.

How does Verastem compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Beam Therapeutics presently has a consensus target price of $49.00, suggesting a potential upside of 96.39%. Verastem has a consensus target price of $13.83, suggesting a potential upside of 85.93%. Given Beam Therapeutics' higher possible upside, research analysts plainly believe Beam Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Beam Therapeutics has a net margin of -54.75% compared to Verastem's net margin of -231.59%. Beam Therapeutics' return on equity of -30.71% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Verastem	-231.59%	-467.49%	-94.54%

In the previous week, Verastem had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Verastem and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.50 beat Verastem's score of 0.27 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has higher revenue and earnings than Verastem. Beam Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.44	-$79.99M	-$0.86	N/A
Verastem	$30.91M	21.80	-$209.47M	-$2.66	N/A

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beam Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, Verastem has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Summary

Beam Therapeutics beats Verastem on 12 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$673.79M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-2.80	14.23	275.49	25.40
Price / Sales	21.80	1,440.84	644.44	86.30
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	10.05	15.45	10.46	6.33
Net Income	-$209.47M	-$22.86M	$3.49B	$358.33M
7 Day Performance	1.64%	-1.21%	0.59%	1.12%
1 Month Performance	9.09%	-3.29%	-1.74%	-2.39%
1 Year Performance	-17.79%	37.74%	18.13%	5.35%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	2.8705 of 5 stars	$7.44 -1.5%	$13.83 +85.9%	-17.8%	$673.79M	$30.91M	N/A	102	News Coverage Analyst Forecast High Trading Volume
NRIX Nurix Therapeutics	2.1282 of 5 stars	$25.52 +1.7%	$34.21 +34.1%	+201.4%	$2.60B	$36.77M	N/A	357	Positive News
CDNA CareDx	2.7676 of 5 stars	$52.37 +4.2%	$51.20 -2.2%	+269.0%	$2.60B	$379.80M	25.30	765
VERA Vera Therapeutics	2.8125 of 5 stars	$34.05 -2.9%	$80.15 +135.4%	+32.9%	$2.53B	N/A	N/A	361	Analyst Forecast Insider Trade Options Volume
PHVS Pharvaris	3.7423 of 5 stars	$38.86 +2.2%	$59.87 +54.1%	+43.4%	$2.49B	N/A	N/A	148	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. NRIX, CDNA, VERA, PHVS, and BEAM

How does Verastem compare to Nurix Therapeutics?

Summary

How does Verastem compare to CareDx?

Summary

How does Verastem compare to Vera Therapeutics?

Summary

How does Verastem compare to Pharvaris?

Summary

How does Verastem compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. NRIX, CDNA, VERA, PHVS, and BEAM

How does Verastem compare to Nurix Therapeutics?

Is VSTM or NRIX more profitable?

Does the media prefer VSTM or NRIX?

Which has more risk & volatility, VSTM or NRIX?

Which has better earnings & valuation, VSTM or NRIX?

Do analysts recommend VSTM or NRIX?

Do insiders and institutionals hold more shares of VSTM or NRIX?

Summary

How does Verastem compare to CareDx?

Which has more volatility & risk, VSTM or CDNA?

Do analysts prefer VSTM or CDNA?

Is VSTM or CDNA more profitable?

Do institutionals & insiders hold more shares of VSTM or CDNA?

Does the media favor VSTM or CDNA?

Which has higher valuation & earnings, VSTM or CDNA?

Summary

How does Verastem compare to Vera Therapeutics?

Is VSTM or VERA more profitable?

Do analysts prefer VSTM or VERA?

Do institutionals and insiders hold more shares of VSTM or VERA?

Does the media favor VSTM or VERA?

Which has preferable earnings and valuation, VSTM or VERA?

Which has more risk and volatility, VSTM or VERA?

Summary

How does Verastem compare to Pharvaris?

Which has preferable valuation & earnings, VSTM or PHVS?

Do institutionals & insiders hold more shares of VSTM or PHVS?

Is VSTM or PHVS more profitable?

Do analysts rate VSTM or PHVS?

Does the media prefer VSTM or PHVS?

Which has more risk and volatility, VSTM or PHVS?

Summary

How does Verastem compare to Beam Therapeutics?

Do analysts prefer BEAM or VSTM?

Is BEAM or VSTM more profitable?

Does the media prefer BEAM or VSTM?

Which has preferable earnings & valuation, BEAM or VSTM?

Do insiders & institutionals have more ownership in BEAM or VSTM?

Which has more risk and volatility, BEAM or VSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools